申请人:ViiV HEALTHCARE UK (NO.5) LIMITED
公开号:US10221129B2
公开(公告)日:2019-03-05
Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth:
阐述了式 I 的化合物,包括其药学上可接受的盐,以及治疗人类免疫缺陷病毒(HIV)感染的组合物和方法: